Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
If
one looks at why patients become resistant to or why they are resistant
de novo to hormonal manipulation, such as tamoxifen or an aromatase
inhibitor, one of the things that we know is that activation of HER2 in
essence can inactivate the estrogen receptor. There was a very nice overview
analysis that looked at hormone therapy trials in the metastatic setting
that was presented at ASCO this year that suggested fairly strongly that
if one was HER2-positive, one was much less likely to benefit from a hormonal
manipulation. Now, if we take that a step further and say if HER2 inactivates
the estrogen receptor might we be able to reactivate the estrogen receptor
for therapeutic purposes by, for instance, combining Herceptin or something
else that inactivates HER2, with the hormonal manipulation. And that’s
a really interesting question that is going to be looked at in a number
of phase II trials in the fairly near future. Of course, to answer that
properly one would need a fairly large phase III trial. But, that’s
a fascinating possibility, the fact that we might be able to use something
like Herceptin, in essence, to allow the patient to respond to a hormonal
manipulation.
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
[Review]. Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl
9):13-19, 2000 Oct.
In
process Current and planned clinical trials with trastuzumab (Herceptin)
[Review]. Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000 Oct. In
process
Clinical
trials of single-agent trastuzumab (Herceptin) [Review]. Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct. In proces
Formestane
is feasible and effective in elderly breast cancer patients with comorbidity
and disability. Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.; Rosso,
R., and Repetto, L. (Reprint available from: Venturino A PO S Lazzaro,
Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer Research & Treatment.
62(3):217-222, 2000 Aug. In process
Critique
of survival update analysis from two phase III anastrozole clinical trials. Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals of Surgical
Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used? Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803, 2000
Apr. No abstract
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
[Review].
Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl 9):13-19, 2000
Oct. In
process
The
use of HER2 testing in the management of breast cancer [Review]. Ravdin, P. Seminars in Oncology. 27(5 Suppl 9):33-42, 2000 Oct. In
process
